| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC2467 |
| Trial ID | NCT04563702 |
| Disease | COVID-19 |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | dsRNA |
| Treatment | VXA-CoV2-1 |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Phase 1 Open-Label, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Vaccine (VXA-CoV2-1) Expressing a SARS-CoV-2 Antigen and dsRNA Adjuvant Administered Orally to Healthy Adult Volunteers VXA-CoV2-1.1-S Boost Substudy: Boost at 1 Year Post Initial Vaccination With an Adenoviral-Vector Based Vaccine VXA-CoV2-1.1-S Expressing a SARS-CoV-2 S Protein in a Subset of Subjects |
| Year | 2020 |
| Country | United States |
| Company sponsor | Vaxart |
| Other ID(s) | VXA-COV2-101 |
| Vector information | |||||||
|
|||||||
| Cohort1: VXA-CoV2-1_dose level 1 | |||||||||
|
|||||||||
| Cohort2: VXA-CoV2-1_dose level 2 | |||||||||
|
|||||||||